Page last updated: 2024-11-05

1,2-epoxybutane

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

1,2-epoxybutane: RN given refers to cpd with unspecified isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID7834
CHEMBL ID1378095
CHEBI ID82326
MeSH IDM0089306

Synonyms (83)

Synonym
ethyloxirane
wln: t3otj b2
nci-c55527
ethylethylene oxide
n-butene-1,2-oxide
1,2-epoxybutane
oxirane, ethyl-
ethylene oxide, ethyl-
1-butylene oxide
1,2-butylene oxide
nsc24240
1,2-butene oxide
1,2-monoepoxybutane
but-1-ene oxide
2-ethyloxirane
1-butene oxide
nsc-24240
butane,2-epoxy-
106-88-7
.alpha.-butylene oxide
butane, 1,2-epoxy-
NCGC00091511-01
1,2-butene oxide (van)
alpha-butylene oxide
ccris 1015
dl-1,2-epoxybutane
nsc 24240
ethyl ethylene oxide
einecs 203-438-2
hsdb 2855
brn 0102411
(+-)-2-ethyloxirane
un3022
1,2-epoxybutane, >=99%
1,2-epoxybutane, 99%
epoxybutane
butene oxide
ebu ,
B0719
AKOS000121478
2-ethyl-oxirane
NCGC00091511-02
C19237
dtxsid6020569 ,
tox21_200207
cas-106-88-7
NCGC00257761-01
dtxcid40569
BBL011530
STL146646
unii-fr67h5388o
ec 203-438-2
1,2-butylene oxide, stabilized [un3022] [flammable liquid]
oxirane, 2-ethyl-
fr67h5388o ,
(+-)-ethyloxirane
1,2-butylene oxide, stabilized
5-17-01-00056 (beilstein handbook reference)
1,2-butyleneoxide
ethyloxirane, (+/-)-
1,2-epoxybutane [iarc]
butene 1,2-epoxide
1,2-butylene epoxide
n-butene-1,2-oxide [hsdb]
2-ethyloxirane, (+/-)-
AKOS017278428
CHEBI:82326 ,
a-butylene oxide
1,2-epoxy butane
ethyl oxirane
1,2 butylene oxide
racemic 1,2-epoxybutane
1,2 epoxybutane
1,2-epoxy-butane
1.2-butylene oxide
Q-200063
(.+/-.)-2-ethyloxirane
CHEMBL1378095
mfcd00005153
1-butene oxide, purum, >=99.0% (gc)
FT-0770886
Q2539029
EN300-21093
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
epoxideAny cyclic ether in which the oxygen atom forms part of a 3-membered ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
AR proteinHomo sapiens (human)Potency28.18380.000221.22318,912.5098AID588516
estrogen nuclear receptor alphaHomo sapiens (human)Potency63.07760.000229.305416,493.5996AID588513; AID743075; AID743079
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (27)

TimeframeStudies, This Drug (%)All Drugs %
pre-199011 (40.74)18.7374
1990's5 (18.52)18.2507
2000's7 (25.93)29.6817
2010's3 (11.11)24.3611
2020's1 (3.70)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 34.86

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index34.86 (24.57)
Research Supply Index3.37 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index47.56 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (34.86)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (7.14%)6.00%
Case Studies1 (3.57%)4.05%
Observational0 (0.00%)0.25%
Other25 (89.29%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]